Crinetics Pharmaceuticals, Inc.
CRNX
$34.47
-$0.57-1.63%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -80.60M | -76.83M | -74.06M | -66.93M | -60.10M |
Total Depreciation and Amortization | 788.00K | 770.00K | 753.00K | 474.00K | 262.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 15.44M | 15.39M | 16.28M | 10.91M | 13.02M |
Change in Net Operating Assets | -308.00K | -2.15M | 11.40M | 2.69M | 8.30M |
Cash from Operations | -64.67M | -62.82M | -45.62M | -52.86M | -38.52M |
Capital Expenditure | -1.03M | -528.00K | -955.00K | -1.33M | -935.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -541.06M | 21.13M | -52.69M | 1.64M | -86.37M |
Cash from Investing | -542.09M | 20.60M | -53.64M | 309.00K | -87.31M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 586.18M | 58.83M | 5.48M | 409.38M | 38.86M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -32.14M | -1.50M | 14.00K | -15.81M | -935.00K |
Cash from Financing | 554.04M | 57.33M | 5.50M | 393.57M | 37.93M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -52.72M | 15.11M | -93.76M | 341.03M | -87.90M |